Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Luxeptinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Cg806, 1616428-23-9, Luxeptinib [usan], Cg026806, Cg'806, Tq6pbx1ju0
    Molecular Formula
    C25H17F4N5O2
    Molecular Weight
    495.4  g/mol
    InChI Key
    MWHHJYUHCZWSLS-UHFFFAOYSA-N
    FDA UNII
    TQ6PBX1JU0
    Luxeptinib is an orally bioavailable reversible, pan-inhibitor of both FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) and Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, luxeptinib targets, non-covalently binds to and inhibits the activity of both FLT3, including both wild-type (WT) FLT3 and FLT3-ITD (internal tandem duplications), tyrosine kinase domain (FLT3-TKD), and gatekeeper (FLT3-F691L) mutant forms, and BTK, including both the WT and its C481S mutant (BTK-C481S) form. This inhibits both uncontrolled FLT3-mediated and B-cell antigen receptor (BCR)-mediated signaling, respectively. This results in the inhibition of proliferation in tumor cells overexpressing FLT3 and BTK. In addition, CG-806 also inhibits, to a lesser degree, other oncogenic kinases, such as MET, RET, discoidin domain-containing receptor 2 (DDR2), Aurora kinase A, and interleukin-2-inducible T-cell kinase (ITK). FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs), and plays a key role in tumor cell proliferation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases essential to BCR signaling, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-(2,4,6-trifluorophenyl)urea
    2.1.2 InChI
    InChI=1S/C25H17F4N5O2/c1-11-9-30-23(32-11)16-5-4-14(17-10-31-24(35)21(16)17)15-3-2-13(8-18(15)27)33-25(36)34-22-19(28)6-12(26)7-20(22)29/h2-9H,10H2,1H3,(H,30,32)(H,31,35)(H2,33,34,36)
    2.1.3 InChI Key
    MWHHJYUHCZWSLS-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CN=C(N1)C2=C3C(=C(C=C2)C4=C(C=C(C=C4)NC(=O)NC5=C(C=C(C=C5F)F)F)F)CNC3=O
    2.2 Other Identifiers
    2.2.1 UNII
    TQ6PBX1JU0
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Cg806

    2. 1616428-23-9

    3. Luxeptinib [usan]

    4. Cg026806

    5. Cg'806

    6. Tq6pbx1ju0

    7. Cg-026806

    8. 1-[3-fluoro-4-[7-(5-methyl-1h-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-(2,4,6-trifluorophenyl)urea

    9. Urea, N-(4-(2,3-dihydro-7-(5-methyl-1h-imidazol-2-yl)-1-oxo-1h-isoindol-4-yl)-3-fluorophenyl)-n'-(2,4,6-trifluorophenyl)-

    10. Urea, N-[4-[2,3-dihydro-7-(5-methyl-1h-imidazol-2-yl)-1-oxo-1h-isoindol-4-yl]-3-fluorophenyl]-n'-(2,4,6-trifluorophenyl)-

    11. Luxeptinib [inn]

    12. Unii-tq6pbx1ju0

    13. Luxeptinib [who-dd]

    14. Chembl4594420

    15. Schembl17219212

    16. Us9758508, Compound 7

    17. Gtpl11671

    18. Bdbm340031

    19. Glxc-25679

    20. Example 7 [us9758508b2]

    21. Nsc791692

    22. Nsc834160

    23. Who 11799

    24. Nsc-791692

    25. Nsc-834160

    26. Hy-139535

    27. Cs-0204021

    28. D96116

    29. 1-{3-fluoro-4-[7-(5-methyl-1h-imidazol-2- Yl)-1-oxo-2,3-dihydro-1h-isoindol-4-yl]- Phenyl}-3-(2,4,6-trifluoro-phenyl)-urea

    30. 3-{3-fluoro-4-[7-(4-methyl-1h-imidazol-2-yl)-1-oxo-2,3-dihydro-1h-isoindol-4-yl]phenyl-1-(2,4,6-trifluorophenyl)urea

    31. 32,72,74,76-tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 495.4 g/mol
    Molecular Formula C25H17F4N5O2
    XLogP33.6
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count4
    Exact Mass495.13183745 g/mol
    Monoisotopic Mass495.13183745 g/mol
    Topological Polar Surface Area98.9 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity811
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1